Current status of ctDNA in precision oncology for hepatocellular carcinoma

19Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The conventional method used to obtain a tumor biopsy for hepatocellular carcinoma (HCC) is invasive and does not evaluate dynamic cancer progression or assess tumor heterogeneity. It is thus imperative to create a novel non-invasive diagnostic technique for improvement in cancer screening, diagnosis, treatment selection, response assessment, and predicting prognosis for HCC. Circulating tumor DNA (ctDNA) is a non-invasive liquid biopsy method that reveals cancer-specific genetic and epigenetic aberrations. Owing to the development of technology in next-generation sequencing and PCR-based assays, the detection and quantification of ctDNA have greatly improved. In this publication, we provide an overview of current technologies used to detect ctDNA, the ctDNA markers utilized, and recent advances regarding the multiple clinical applications in the field of precision medicine for HCC.

Cite

CITATION STYLE

APA

Li, Y., Zheng, Y., Wu, L., Li, J., Ji, J., Yu, Q., … Guo, C. (2021, December 1). Current status of ctDNA in precision oncology for hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research. BioMed Central Ltd. https://doi.org/10.1186/s13046-021-01940-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free